S'abonner

Intestinal microbiota in infants at high risk for allergy: Effects of prebiotics and role in eczema development - 05/04/18

Doi : 10.1016/j.jaci.2017.05.054 
Harm Wopereis, BSc a, b, , Kathleen Sim, MRCPCH, PhD c, Alexander Shaw, PhD c, John O. Warner, MD, FMedSci c, Jan Knol, PhD a, b, J. Simon Kroll, MA, FMedSci c
a Danone Nutricia Research, Utrecht, The Netherlands 
b Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands 
c Department of Medicine, Section of Paediatrics, Imperial College London, London, United Kingdom 

Corresponding author: Harm Wopereis, BSc, Danone Nutricia Research, Uppsalalaan 12, 3584 CT Utrecht, The Netherlands.Danone Nutricia ResearchUppsalalaan 12Utrecht3584 CTThe Netherlands

Abstract

Background

Development of the gut microbiota in infancy is important in maturation of the immune system. Deviations in colonization patterns have been associated with allergic manifestations such as eczema, but exact microbiome dysfunctions underlying allergies remain unclear. We studied the gut microbiota of 138 infants at increased risk of allergy, participating in a clinical trial investigating the effectiveness of a partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides on the prevention of eczema.

Objective

The effects of interventions and breast-feeding on fecal microbiota were investigated. Additionally, we aimed to identify microbial patterns associated with the onset of eczema.

Methods

Bacterial taxonomic compositions in the first 26 weeks of life were analyzed by using 16S rRNA gene sequencing. Additionally, fecal pH and microbial metabolite levels were measured.

Results

Fecal microbial composition, metabolites, and pH of infants receiving partially hydrolyzed protein formula supplemented with nondigestible oligosaccharides was closer to that of breast-fed infants than that of infants receiving standard cow's milk formula. Infants with eczema by 18 months showed discordant development of bacterial genera of Enterobacteriaceae and Parabacteroides species in the first 26 weeks, as well as decreased acquisition of lactate-utilizing bacteria producing butyrate, namely Eubacterium and Anaerostipes species, supported by increased lactate and decreased butyrate levels.

Conclusions

We showed that a partially hydrolyzed protein infant formula with specific prebiotics modulated the gut microbiota closer to that of breast-fed infants. Additionally, we identified a potential link between microbial activity and onset of eczema, which might reflect a suboptimal implementation of gut microbiota at specific developmental stages in infants at high risk for allergy.

Le texte complet de cet article est disponible en PDF.

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Key words : Allergy, eczema, gastrointestinal, microbiome, microbiota, short-chain fatty acids, butyrate, lactate, prebiotics, infants

Abbreviations used : LUB, MCPT, OTU, pHF-OS, PRC, SCFA


Plan


 This study was funded by Danone Nutricia Research. Work in the Kroll laboratory was supported by funding from the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial Healthcare NHS Trust and Imperial College London.
 Disclosure of potential conflict of interest: H. Wopereis and J. Knol are employees of Danone Nutricia Research. K. Sim, A. Shaw, and J. S. Kroll have received grants from the UK National Institute of Health Research. J. O. Warner has received a grant, travel support, and fees for participation in review activities from Danone Nutricia Research; is on scientific advisory boards for Airsonette, MicroTest Matrices, and UCB; has provided expert testimony for a private legal firm; has received grants from Airsonette; has received payment for lectures from Airsonette and Pfizer China; owns stock/stock options in London Allergy Clinic; and has received travel support from Monash University and Hospital.


© 2017  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 141 - N° 4

P. 1334 - avril 2018 Retour au numéro
Article précédent Article précédent
  • Toll-like receptor 7/8 agonists stimulate plasmacytoid dendritic cells to initiate TH17-deviated acute contact dermatitis in human subjects
  • Natalie Garzorz-Stark, Felix Lauffer, Linda Krause, Jenny Thomas, Anne Atenhan, Regina Franz, Sophie Roenneberg, Alexander Boehner, Manja Jargosch, Richa Batra, Nikola S. Mueller, Stefan Haak, Christina Groß, Olaf Groß, Claudia Traidl-Hoffmann, Fabian J. Theis, Carsten B. Schmidt-Weber, Tilo Biedermann, Stefanie Eyerich, Kilian Eyerich
| Article suivant Article suivant
  • Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort
  • George du Toit, Peter H. Sayre, Graham Roberts, Kaitie Lawson, Michelle L. Sever, Henry T. Bahnson, Helen R. Fisher, Mary Feeney, Suzana Radulovic, Monica Basting, Marshall Plaut, Gideon Lack

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.